Al-Kaabawi Ahmed, Landberg Eva, Martí Magalí, Severin Elisabet, Tingö Lina, Duchén Karel, Jenmalm Maria C
Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden.
Department of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Pediatr Allergy Immunol. 2025 Aug;36(8):e70162. doi: 10.1111/pai.70162.
Human milk oligosaccharides (HMOs) are complex carbohydrates that act as prebiotics, supporting infants' gut microbial colonization and immune development. HMO levels are influenced by several maternal factors, including genetics, diet, and health status. In this study, we aim to investigate the effects of ω-3 PUFA (polyunsaturated fatty acids) and Limosilactobacillus (L.) reuteri supplementation on HMO levels in colostrum and mature milk. Another aim is to compare HMO levels between allergic and non-allergic mothers and to explore the correlation between HMOs and secretory immunoglobulin A (SIgA) in milk.
Milk samples (n = 136) were collected from mothers enrolled in a clinical trial (PROOM-3) designed to investigate the effect of pre- and postnatal supplementation with ω-3 PUFA and L. reuteri on allergy development in early childhood. HMOs were measured in colostrum and mature milk collected 3 months postpartum using high-performance anion exchange chromatography. SIgA was measured in colostrum, 1-, 2-, 3-, and 4-month milk using ELISA.
The supplements did not affect HMO levels in colostrum or mature milk. However, maternal supplementation with ω-3 PUFA decreased the HMO diversity over time. Additionally, allergic mothers expressed significantly lower levels of several HMOs compared to non-allergic mothers. Additionally, SIgA correlated positively with fucosylated and negatively with sialylated HMOs.
Supplementation with ω-3 PUFA could reduce the HMO diversity over the course of lactation. Also, maternal allergy seems to be associated with a reduction in levels of several HMOs. Furthermore, there is a possible dynamic interplay between HMOs and SIgA in milk.
ClinicalTrials.gov-ID: NCT01542970.
人乳寡糖(HMOs)是一类复杂的碳水化合物,可作为益生元,促进婴儿肠道微生物定植和免疫发育。HMO水平受多种母亲因素影响,包括遗传、饮食和健康状况。在本研究中,我们旨在调查ω-3多不饱和脂肪酸(PUFA)和罗伊氏乳杆菌(L. reuteri)补充剂对初乳和成熟乳中HMO水平的影响。另一个目的是比较过敏和非过敏母亲之间的HMO水平,并探索乳汁中HMO与分泌型免疫球蛋白A(SIgA)之间的相关性。
从参与一项临床试验(PROOM-3)的母亲中收集乳汁样本(n = 136),该试验旨在研究产前和产后补充ω-3 PUFA和罗伊氏乳杆菌对儿童早期过敏发展的影响。使用高效阴离子交换色谱法测量产后3个月收集的初乳和成熟乳中的HMOs。使用酶联免疫吸附测定法(ELISA)测量初乳、产后1、2、3和4个月乳汁中的SIgA。
补充剂对初乳或成熟乳中的HMO水平没有影响。然而,母亲补充ω-3 PUFA会随着时间的推移降低HMO的多样性。此外,与非过敏母亲相比,过敏母亲的几种HMO水平明显较低。此外,SIgA与岩藻糖基化HMO呈正相关,与唾液酸化HMO呈负相关。
补充ω-3 PUFA可能会在哺乳期降低HMO的多样性。此外,母亲过敏似乎与几种HMO水平的降低有关。此外,乳汁中HMO和SIgA之间可能存在动态相互作用。
ClinicalTrials.gov标识符:NCT01542970。